Related Experiment Videos
Amniotic fluid platelet factor 4 and beta-thromboglobulin
A A Saleh1, T Ozawa, M P Dombrowski
1Department of Obstetrics and Gynecology, Hutzel Hospital, Wayne State University, Detroit, Mich.
Insights
Platelet activating factor (PAF) may influence fetal development. This study found higher levels of beta-thromboglobulin (BTG) and platelet factor 4 (PF4) in amniotic fluid from genetic amniocentesis compared to lung maturity samples.
Area of Science:
- Reproductive Biology
- Fetal Development
- Hematology
Background:
- Platelet activating factor (PAF) is a potent platelet activator found in human embryos and fetuses.
- PAF is hypothesized to play a role in fetal lung maturation.
- The impact of PAF on fetal platelet activation, indicated by beta-thromboglobulin (BTG) and platelet factor 4 (PF4) release, remains uninvestigated.
Purpose of the Study:
- To investigate the levels of beta-thromboglobulin (BTG) and platelet factor 4 (PF4) in amniotic fluid.
- To explore the potential relationship between BTG, PF4, and fetal lung maturation.
- To determine the origin of BTG and PF4 in the amniotic fluid.
Main Methods:
- Measurement of BTG and PF4 concentrations in amniotic fluid samples.
- Samples were obtained from 78 genetic amniocenteses and 35 pulmonary maturity amniocenteses.
- Correlation analysis with pulmonary maturity parameters: lecithin to sphingomyelin ratio and phosphatidylglycerol concentration.
Main Results:
- BTG and PF4 levels were significantly higher in genetic amniocentesis samples compared to lung maturity samples (p < 0.001).
- No correlation was found between BTG, PF4 levels and established pulmonary maturity parameters.
- Findings suggest that BTG and PF4 originate from the fetus.
Conclusions:
- Fetal-derived BTG and PF4 are present in amniotic fluid.
- These markers do not appear to directly reflect fetal lung maturity based on current parameters.
- Further research is needed to elucidate the role of fetal platelets and PAF in pregnancy.
Abstract:
Platelet activating factor (PAF), a powerful platelet activator, has been identified in human embryos and fetuses, and may induce fetal lung maturation. The potential effect of PAF on fetal platelets as indicated by release of beta-thromboglobulin (BTG) and platelet factor 4 (PF4) has not been investigated. We measured BTG and PF4 in amniotic fluid from 78 genetic and 35 pulmonary maturity amniocenteses. BTG and PF4 were higher in the genetic amniocentesis samples (p < 0.001 in each case) than in the lung maturity samples. BTG and PF4 did not correlate with the pulmonary maturity parameters as measured by the lecithin to sphingomyelin ratio and phosphatidylglycerol concentration. Our findings suggest a fetal origin of BTG and PF4 in amniotic fluid.